Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Impact of Cardiomyopathy and Arrhythmia Genetic Testing on Clinical Management Decisions.
Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2026
Leadless Pacemaker Implantation in a Child with Repaired Congenital Heart Disease and Severe Kyphoscoliosis-Proof of Concept.
Journal: Pediatric cardiology
Published: July 07, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: June 17, 2026
Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM.
Journal: JACC. Heart failure
Published: June 08, 2026
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II.
Journal: JACC. Heart failure
Published: February 16, 2026
Management of Dialysis for Patients Receiving Mechanical Circulatory Support.
Journal: Journal of the American Society of Nephrology : JASN
Published: January 21, 2026
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116].
Journal: American heart journal
Published: December 19, 2025
Total artificial hearts: an evolution on the horizon.
Journal: European heart journal
Published: October 16, 2025
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
Journal: Journal of the American College of Cardiology
Published: October 11, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Journal: Journal of the American College of Cardiology
Published: October 11, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
Published: September 01, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Journal: Journal of the American College of Cardiology
Published: July 24, 2025
Last Updated: 09/26/2026